Aper­tu­ra and Ata­lan­ta re­duce head­count en route to­ward the clin­ic

Two cen­tral ner­vous sys­tem dis­or­der biotechs laid off em­ploy­ees re­cent­ly.

New York gene ther­a­py start­up Aper­tu­ra and Boston RNAi biotech Ata­lan­ta Ther­a­peu­tics have trimmed their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER